Background & Aims Patients with Crohn's disease (CD) treated with ustekinumab who
experience inadequate response, or loss of response after standard induction and/or …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

Background There is no head‐to‐head trial comparing ustekinumab and vedolizumab in
patients with Crohn's disease (CD) refractory to anti‐tumour necrosis factor (anti‐TNF). Aim …

Background The approved maintenance regimens for ustekinumab in Crohn's disease [CD]
are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will …

METHODS: This study used a retrospective, multicenter, multinational consortium of UST-
treated CD patients. Data included patient demographics, disease phenotype, disease …

Crohn's disease (CD) is a relapsing and progressive condition characterized by diarrhea,
abdominal pain, weight loss, and hematochezia that results in serious complications such as …

Abstract Background Many patients with Crohn's disease (CD) who lose response to the
standard ustekinumab dose interval of every 8 weeks (q8w) undergo dose intensification to …

Study Design This retrospective cohort study included adults with UC (ICD-10-CM 51x)
initiating ustekinumab at Brigham and Women's Hospital, Massachusetts General Hospital …

Background Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and
IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance …

Background Current data on dual biologic therapy in children are limited. This multicenter
study aimed to evaluate the effectiveness and safety of dual therapy in pediatric patients with …